导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.10% | 3896/4773 |
| 近一周 | -4.20% | 5036/5465 |
| 近一月 | -6.41% | 4170/5421 |
| 近一季 | -5.52% | 2097/5231 |
| 近半年 | -14.09% | 3958/4920 |
| 近一年 | -10.75% | 3462/4394 |
| 近两年 | 16.64% | 2705/2954 |
| 近三年 | -1.76% | 1954/2253 |
| 成立以来 | 120.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.38% 2268/4961 |
-8.01% 3826/5312 |
- - |
- - |
| 2025 | 9.28% 2870/4813 |
1.48% 1614/3635 |
-3.06% 3410/4076 |
9.93% 3327/4524 |
1.06% 1561/4813 |
| 2024 | 11.20% 1340/3463 |
6.35% 296/2808 |
-4.95% 1598/3014 |
17.58% 1164/3129 |
-6.44% 2655/3463 |
| 2023 | -9.12% 1111/2656 |
6.49% 682/2280 |
-7.16% 1792/2385 |
-0.77% 446/2515 |
-7.37% 2131/2655 |
| 2022 | -19.25% 822/2207 |
-16.50% 1135/1919 |
6.83% 596/2016 |
-12.24% 681/2113 |
3.15% 758/2208 |
| 2021 | -12.74% 1131/1822 |
-1.10% 431/1255 |
-3.70% 1251/1330 |
-10.59% 1228/1466 |
2.47% 583/1822 |
| 2020 | 34.12% 443/1250 |
-14.47% 961/1028 |
15.50% 495/1067 |
13.21% 338/1164 |
19.92% 65/1184 |
| 2019 | 60.02% 55/1092 |
40.64% 51/754 |
1.62% 118/804 |
1.97% 339/850 |
9.81% 192/918 |
| 2018 | -26.28% 380/834 |
- - |
- - |
- - |
-9.11% 127/691 |
| 2017 | 49.20% 11/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.54% 198/605 |
- - |
- - |
- - |
- - |
| 2015 | 15.61% 138/575 |
- - |
- - |
- - |
- - |
| 2014 | 55.32% 53/237 |
- - |
- - |
- - |
- - |
| 2013 | -4.55% 89/186 |
- - |
- - |
- - |
- - |
| 2012 | 5.20% 76/140 |
- - |
- - |
- - |
- - |
| 2011 | -31.14% 94/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 工银深证红利ETF VS. 长安沪深300非周期A(740101) |